Conveners
Radiopharmaceuticals: RPH1
- Martina Benešová-Schäfer
- Constantin Mamat (HZDR)
Radiopharmaceuticals: Poster session
- There are no conveners in this block
-
Kattesh Katti (University of Missouri)5/14/26, 10:30 AMRadiopharmaceutical Chemistry, Labelled CompoundsInvited
Background: There is extensive clinical evidence that cancer patients receiving radiation therapy, during and after treatments, undergo severe suppression in cancer-killing immune responses. Although radiation therapy(TR) has proven to be highly effective in killing tumor cells, its collateral effects in causing extensive damage to healthy/normal cells, especially RT’s adverse and irreversible...
Go to contribution page -
Antonia Denkova (TU Delft)5/14/26, 10:56 AMRadiopharmaceutical Chemistry, Labelled CompoundsVerbal
Auger electrons are known for their high linear energy transfer which can induce clustered DNA damage, leading to highly efficient cell death. Therefore, Auger electrons are ideal for attacking small metastatic tumors. In many cases, Auger electrons are typically emitted alongside other radiation such as gamma rays or positrons, which enable diagnostic imaging applications. Despite these...
Go to contribution page -
Constantin Mamat (HZDR)5/14/26, 11:12 AMRadiopharmaceutical Chemistry, Labelled CompoundsVerbal
A detailed understanding of the coordination chemistry of heavy group 2 metal ions, particularly barium as a surrogate for radium, is essential for advancing radiopharmaceutical applications of radium. This is of particular importance as radium-223 is currently the only clinically approved therapeutic alpha-emitter (by EMA and FDA). However, its clinical applications remains limited. To date,...
Go to contribution page -
Lu Liu5/14/26, 11:28 AMRadiopharmaceutical Chemistry, Labelled CompoundsVerbal
Astatine (At, Z = 85) is a radioelement belonging to the halogen group. One of its isotopes, 211At is considered a highly promising candidate for targeted alpha therapy due to its favorable physical properties, including a half-life of 7.2 h and a 100% alpha-emission yield. A key prerequisite for its medical application is the development of stable labeling strategies that ensure the reliable...
Go to contribution page -
Rodrigo Castro Biondo (Helmholtz-Zentrum Dresden-Rossendorf)5/14/26, 11:44 AMRadiopharmaceutical Chemistry, Labelled CompoundsVerbal
Radiometals play an essential role in the context of both radiopharmacy and radioecology, two scientific fields that seem unrelated but that are, nevertheless, connected through the fundamentals of radiochemistry. In either case, the selective and stable coordination of radiometal ions represent key objectives in the development of ligands. While radiopharmacy covers the use of radiolabeled...
Go to contribution page -
Prof. Pavol Rajec (BIONT a.s. Bratislava)5/14/26, 5:15 PMRadiopharmaceutical Chemistry, Labelled CompoundsPoster
The development of radiopharmaceuticals labeled with positron-emitting radionuclides has significantly expanded the capabilities of molecular imaging in nuclear medicine. Among these radionuclides, gallium-68 (⁶⁸Ga) and copper-64 (⁶⁴Cu) have attracted considerable attention due to their favorable decay properties and compatibility with a wide range of targeting molecules. This abstract...
Go to contribution page -
Daniela Veselá (Research Centre Řež)5/14/26, 5:18 PMRadiopharmaceutical Chemistry, Labelled CompoundsPoster
Glioblastoma multiforme (GBM) is among the most aggressive human cancers, where the current combination of surgery, radiotherapy, and chemotherapy yields only limited extension of patient survival. The NuCapCure project introduces a radically new concept for treating deep-seated tumours by synergistically combining protons, neutrons, and the intracellular biochemistry. The core idea is the...
Go to contribution page -
Barbora Brzková (Fakulta jaderná a fyzikálně inženýrská, ČVUT)5/14/26, 5:21 PMRadiopharmaceutical Chemistry, Labelled CompoundsPoster
Radioimmunoconjugates combine the targeting specificity of monoclonal antibodies with the therapeutic effects of radionuclides. Terbium 161 has emerged as a promising candidate owing to its favorable decay properties, including β⁻ emission and conversion/Auger electrons.
Go to contribution page
The monoclonal antibodies used in this study were rituximab and bevacizumab. Rituximab is a chimeric monoclonal antibody... -
Tereza Janská (Katedra jaderné chemie, Fakulta jaderná a fyzikálně inženýrská, České vysoké učení technické v Praze)5/14/26, 5:24 PMRadiopharmaceutical Chemistry, Labelled CompoundsPoster
Certain cancers overexpress specific receptors that can be targeted by monoclonal antibodies, such as HER2, which is overexpressed in breast cancer and targeted by pertuzumab. Radioligand therapy builds on this concept by combining antibody specificity with radionuclide-mediated cytotoxicity for selective tumor irradiation.
Go to contribution page
Terbium‑161 has recently emerged as a promising alternative to...